Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice
Department of Neurology, Henry Ford Health Sciences Center, 2799 West Grand Boulevard, Detroit, MI 48202, USA. Experimental Neurology
(Impact Factor: 4.7).
10/2005; 195(1):16-26. DOI: 10.1016/j.expneurol.2005.03.018
We investigated the treatment of remitting-relapsing experimental autoimmune encephalomyelitis (EAE) in mice with human bone marrow stromal cells (hBMSCs). hBMSCs were injected intravenously into EAE mice upon onset of paresis. Neurological functional tests were scored daily by grading clinical signs (score 0-5). Immunohistochemistry was performed to measure the transplanted hBMSCs, cell proliferation (bromodeoxyuridine, BrdU), oligodendrocyte progenitor cells (NG2), oligodendrocytes (RIP), and brain-derived neurotrophic factor (BDNF). The maximum clinical score and the average clinical scores were significantly decreased in the hBMSC-transplanted mice compared to the phosphate-buffered-saline-treated EAE controls, indicating a significant improvement in function. Demyelination significantly decreased, and BrdU(+) and BDNF(+) cells significantly increased in the hBMSC-treated mice compared to controls. Some BrdU(+) cells were colocalized with NG2(+) and RIP(+) immunostaining. hBMSCs also significantly reduced the numbers of vessels containing inflammatory cell infiltration. These data indicate that hBMSC treatment improved functional recovery after EAE in mice, possibly, via reducing inflammatory infiltrates and demyelination areas, stimulating oligodendrogenesis, and by elevating BDNF expression.
Available from: Veronika E Neubrand
- "In contrast, mesenchymal stem cells (MSCs) isolated from many adult tissues have recently emerged as potent immunomodulatory cells with therapeutic applications in regenerative medicine (Phinney and Prockop, 2007) and in the treatment of inflammatory and autoimmune disorders (Uccelli and Prockop, 2010). Thus, MSCs derived from bone marrow and adipose tissue were shown to ameliorate experimental autoimmune encephalomyelitis and protected neurons from neuroinflammation in experimental models of brain ischemia and brain injury (Constantin et al., 2009; Uccelli et al., 2011; Zappia et al., 2005; Zhang et al. 2005). Among their multimodal actions, MSCs seem to modulate microglia activation (Kim et al., 2009; Zhou et al., 2009) although the mechanisms involved are largely unknown. "
[Show abstract] [Hide abstract]
ABSTRACT: Activated microglia play a central role in the course of neurodegenerative diseases as they secrete cytotoxic substances which lead to neuronal cell death. Understanding the mechanisms that drive activation of microglia is essential to reverse this phenotype and to protect from neurodegeneration. With some exceptions, evidence indicates that changes in cell morphology from a star shape to a round and flat shape accompany the process of activation in microglia. In this study, we investigated the effect of adipose-tissue-derived mesenchymal stem cells (ASCs), which exert important anti-inflammatory actions, in microglia morphology. Microglia exposed to ASCs or their secreted factors (conditioned medium) underwent a cell shape change into a ramifying morphology in basal and inflammatory conditions, similar to that observed in microglia found in healthy brain. Colony-stimulating factor-1 secreted by ASCs played a critical role in the induction of this phenotype. Importantly, ASCs reversed the activated round phenotype induced in microglia by bacterial endotoxins. The ramifying morphology of microglia induced by ASCs was associated with a decrease of the proinflammatory cytokines tumor necrosis factor-α and interleukin-6, an increase in phagocytic activity, and the upregulation of neurotrophic factors and of Arginase-1, a marker for M2-like regulatory microglia. In addition, activation of the phosphoinositide-3-kinase/Akt pathway and the RhoGTPases Rac1 and Cdc42 played a major role in the acquisition of this phenotype. Therefore, these RhoGTPases emerge as key players in the ramification of microglia by anti-inflammatory agents like ASCs, being fundamental to maintain the tissue-surveying, central nervous system supporting state of microglia in healthy conditions. GLIA 2014.
Glia 12/2014; 62(12). DOI:10.1002/glia.22714 · 6.03 Impact Factor
Available from: Debayon Paul
- "The muted in vivo efficacy of BM - MSCs that we observed is consistent with previous reports that showed only mild ( Gordon et al . , 2008 ; Zhang et al . , 2005 ) or negligible ( Payne et al . , 2013 ) effects in the EAE mouse model . Inter - estingly , BM - MSC#6 , the BM - MSC line that caused a modest reduction in EAE disease scores in the preonset model at passage 2 ( Figure 3C ) , failed to show any thera - peutic effects when used at passage 4 during the anti - iL - 6 antibody experiment "
[Show abstract] [Hide abstract]
ABSTRACT: Current therapies for multiple sclerosis (MS) are largely palliative, not curative. Mesenchymal stem cells (MSCs) harbor regenerative and immunosuppressive functions, indicating a potential therapy for MS, yet the variability and low potency of MSCs from adult sources hinder their therapeutic potential. MSCs derived from human embryonic stem cells (hES-MSCs) may be better suited for clinical treatment of MS because of their unlimited and stable supply. Here, we show that hES-MSCs significantly reduce clinical symptoms and prevent neuronal demyelination in a mouse experimental autoimmune encephalitis (EAE) model of MS, and that the EAE disease-modifying effect of hES-MSCs is significantly greater than that of human bone-marrow-derived MSCs (BM-MSCs). Our evidence also suggests that increased IL-6 expression by BM-MSCs contributes to the reduced anti-EAE therapeutic activity of these cells. A distinct ability to extravasate and migrate into inflamed CNS tissues may also be associated with the robust therapeutic effects of hES-MSCs on EAE.
Stem Cell Reports 07/2014; 3(1):1-16. DOI:10.1016/j.stemcr.2014.04.020 · 5.37 Impact Factor
Available from: Guangfeng Zhao
- "On the other hand, MSCs also are low immunogenic cells and allogenic MSCs are not rejected by immune system. Recently, several studies from our and other groups,  have reported that treatment with human bone marrow-, adipose- or umbilical cords- derived MSCs exhibited early efficacy in attenuating the progression of several experimental inflammatory diseases in murine models, including experimental arthritis, colitis , , and autoimmune encephalomyelitis. There are two reasons why those experiments are reasonable. "
[Show abstract] [Hide abstract]
ABSTRACT: Pre-eclampsia (PE) is thought to be a pregnancy-induced autoimmune disease. Despite several strategies carried out for targeting specific factors relevant to its pathogenesis, PE remains potentially fatal to some patients. Here, we reported a way to isolate mesenchymal stem cells (MSCs) from decidua. The MSCs not only exhibited differentiation and self-renewal capacities, they also possessed immunomodulatory functions and secreted some soluble mediators including IL-6, TGF-β, IDO, VEGF and COX-2. Most importantly, the MSCs were specifically provided with the ability to suppress T cells proliferation by IDO in response to inflammatory cytokine IFN-γ. Moreover, we developed a Th1 cell-induced PE mouse model which displayed a high level of pathogenesis factor TNF-α. Strikingly, MSCs-based therapy significantly ameliorated both clinical and histopathological severity of PE symptoms including decreasing the blood pressure and proteinuria, suppressing glomerulonephritis, protecting the feto-placental development. The therapy also reversed abnormal TNF-α expression in uterine and splenic lymphocytes. These data suggest that MSCs may ameliorate Th1-induced PE-like symptoms in mice via the suppression of TNF-α and MSCs-based therapy may provide a potential novel method for PE.
PLoS ONE 02/2014; 9(2):e88036. DOI:10.1371/journal.pone.0088036 · 3.23 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.